BR0314552A - Métodos para prognosticar elevações de colesterol durante terapia imunossupressora - Google Patents

Métodos para prognosticar elevações de colesterol durante terapia imunossupressora

Info

Publication number
BR0314552A
BR0314552A BR0314552-2A BR0314552A BR0314552A BR 0314552 A BR0314552 A BR 0314552A BR 0314552 A BR0314552 A BR 0314552A BR 0314552 A BR0314552 A BR 0314552A
Authority
BR
Brazil
Prior art keywords
methods
predict
immunosuppressive therapy
elevations during
cholesterol
Prior art date
Application number
BR0314552-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Sridhar Kudaravalli
Mihael Hristos Polymeropoulos
Rosarelis Torres
Curt Douglas Wolfgang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314552(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0314552A publication Critical patent/BR0314552A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR0314552-2A 2002-09-30 2003-09-29 Métodos para prognosticar elevações de colesterol durante terapia imunossupressora BR0314552A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41512302P 2002-09-30 2002-09-30
PCT/EP2003/010798 WO2004029618A2 (en) 2002-09-30 2003-09-29 Methods to predict cholesterol elevations during immunosuppressant therapy

Publications (1)

Publication Number Publication Date
BR0314552A true BR0314552A (pt) 2005-08-09

Family

ID=32043422

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314552-2A BR0314552A (pt) 2002-09-30 2003-09-29 Métodos para prognosticar elevações de colesterol durante terapia imunossupressora

Country Status (13)

Country Link
US (2) US7732134B2 (enExample)
EP (1) EP1549770B1 (enExample)
JP (1) JP4575775B2 (enExample)
CN (1) CN100453650C (enExample)
AT (1) ATE389034T1 (enExample)
AU (1) AU2003287955B2 (enExample)
BR (1) BR0314552A (enExample)
CA (1) CA2500979A1 (enExample)
DE (1) DE60319719T2 (enExample)
ES (1) ES2302959T3 (enExample)
IL (1) IL167639A (enExample)
PT (1) PT1549770E (enExample)
WO (1) WO2004029618A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007147600A (ru) * 2005-05-31 2009-07-20 Новартис АГ (CH) КОМБИНАЦИЯ ИНГИБИТОРОВ ГИДРОКСИ-МЕТИЛГЛУТАРИЛ-КОЭНЗИМ-А-РЕДУКТАЗЫ (ГМГ-КоА-РЕДУКТАЗЫ) И ИНГИБИТОРОВ МИШЕНИ РАПАМИЦИНА МЛЕКОПИТАЮЩИХ (МРМ)
JP2013509883A (ja) 2009-11-06 2013-03-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 臓器移植患者における移植片拒絶反応の非侵襲的診断方法
CA2793170C (en) * 2010-03-15 2018-04-17 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
EP1463745A4 (en) * 2001-11-19 2007-11-07 Interleukin Genetics Inc FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 SITE AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES

Also Published As

Publication number Publication date
CN100453650C (zh) 2009-01-21
WO2004029618A2 (en) 2004-04-08
US20060246439A1 (en) 2006-11-02
JP4575775B2 (ja) 2010-11-04
ES2302959T3 (es) 2008-08-01
ATE389034T1 (de) 2008-03-15
AU2003287955B9 (en) 2004-04-19
WO2004029618A3 (en) 2004-06-17
PT1549770E (pt) 2008-06-24
CA2500979A1 (en) 2004-04-08
EP1549770B1 (en) 2008-03-12
US7732134B2 (en) 2010-06-08
IL167639A (en) 2011-10-31
HK1084445A1 (zh) 2006-07-28
AU2003287955B2 (en) 2007-06-21
DE60319719T2 (de) 2009-03-12
EP1549770A2 (en) 2005-07-06
US20100184798A1 (en) 2010-07-22
JP2006500930A (ja) 2006-01-12
DE60319719D1 (de) 2008-04-24
CN1685062A (zh) 2005-10-19
AU2003287955A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
TNSN05300A1 (en) Treatment with anti-vegf antibodies
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
DE60325628D1 (de) Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
MY151032A (en) Treatment of tnf? related disorders
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
MXPA04006572A (es) Terapia de combinacion antivirica.
PT1427409E (pt) Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
BR0314552A (pt) Métodos para prognosticar elevações de colesterol durante terapia imunossupressora
EA200601871A1 (ru) Способы лечения аутоиммунных и воспалительных заболеваний
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
NO20053903D0 (no) Nukleotidlipidesterderivater.
BR0113646A (pt) Tratamento de distúrbios inflamatórios
IL139144A0 (en) Mycobacterial inhibitors
BRPI0512709A (pt) métodos para prognóstico da resposta terapêutica a agentes atuando no receptor do hormÈnio do crescimento
EP1549664A4 (en) MURINES ORTHOLOGY OF THE HUMAN DISRUPTED-IN SCHIZOPHRENIA 1-GENES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2273 DE 29/07/2014.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.